Evidence map›Paper›PMID 29185848›Full record

ArticlemAbs2018

Monoclonal antibodies targeting the disintegrin-like domain of ADAMDEC1 modulates the proteolytic activity and enables quantification of ADAMDEC1 protein in human plasma.

Jacob Lund, Anne Mette Elimar Bitsch, Morten Grønbech Rasch, Mari Enoksson, Linda Troeberg, Hideaki Nagase, Mette Loftager, Michael Toft Overgaard, Helle Heibroch Petersen

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Monoclonal antibodies against metzincin targets.British journal of pharmacology · 2019
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jacob Lunda Department of Haemophilia Biochemistry , Novo Nordisk A/S , Måløv , Denmark.
Anne Mette Elimar Bitscha Department of Haemophilia Biochemistry , Novo Nordisk A/S , Måløv , Denmark.ORCID 0000-0002-5367-4629
Morten Grønbech Raschc Department of Antibody Technology , Novo Nordisk A/S , Måløv , Denmark.
Mari Enokssona Department of Haemophilia Biochemistry , Novo Nordisk A/S , Måløv , Denmark.
Linda Troebergd Kennedy Institute of Rheumatology, University of Oxford , Oxford , United Kingdom.
Hideaki Nagased Kennedy Institute of Rheumatology, University of Oxford , Oxford , United Kingdom.
Mette Loftagere Department of Haemophilia Research Bioanalysis , Novo Nordisk A/S , Måløv , Denmark.
Michael Toft Overgaardb Department of Chemistry and Bioscience , Aalborg University , Aalborg , Denmark.ORCID 0000-0002-1423-2481
Helle Heibroch Petersena Department of Haemophilia Biochemistry , Novo Nordisk A/S , Måløv , Denmark.
Novo Nordisk (Denmark) · DKUniversity of Oxford · GBAalborg University · DK

Funding

Arthritis Research UK 19466Arthritis Research UK 20205Arthritis Research UK 20887
6 · The paper itself

Abstract

Decysin-1 (ADAMDEC1) is an orphan ADAM-like metalloprotease with unknown biological function and a short domain structure. ADAMDEC1 mRNA has previously been demonstrated primarily in macrophages and mature dendritic cells. Here, we generated monoclonal antibodies (mAbs) against the mature ADAMDEC1 protein, as well as mAbs specific for the ADAMDEC1 pro-form, enabling further investigations of the metalloprotease. The generated mAbs bind ADAMDEC1 with varying affinity and represent at least six different epitope bins. Binding of mAbs to one epitope bin in the C-terminal disintegrin-like domain efficiently reduces the proteolytic activity of ADAMDEC1. A unique mAb, also recognizing the disintegrin-like domain, stimulates the caseinolytic activity of ADAMDEC1 while having no significant effect on the proteolysis of carboxymethylated transferrin. Using two different mAbs binding the disintegrin-like domain, we developed a robust, quantitative sandwich ELISA and demonstrate secretion of mature ADAMDEC1 protein by primary human macrophages. Surprisingly, we also found ADAMDEC1 present in human plasma with an approximate concentration of 0.5 nM. The presence of ADAMDEC1 both in human plasma and in macrophage cell culture supernatant were biochemically validated using immunoprecipitation and Western blot analysis demonstrating that ADAMDEC1 is secreted in a mature form.

Indexed as

ADAM ProteinsAnimalsAntibodies, MonoclonalAntibody SpecificityBinding Sites, AntibodyCarboxylic AcidsCells, CulturedEnzyme-Linked Immunosorbent AssayEpitopesHumansKineticsMacrophagesMethylationMiceProtease InhibitorsProtein BindingADAM ProteinsAntibodies, MonoclonalCarboxylic AcidsdecysinEpitopesProtease InhibitorsTransferrinADAMDEC1disintegrinELISAMetalloproteaseplasmaquantification

Identifiers

PMID29185848
PMCPMC5800386
OpenAlexW2768526286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.